KALA BIO, Inc. KALA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -64.20% | -62.09% | 134.68% | 3.05% | 7.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -84.17% | -83.08% | 8.10% | 11.42% | 12.88% |
| Operating Income | 84.17% | 83.08% | -8.10% | -11.42% | -12.88% |
| Income Before Tax | 85.83% | 81.88% | 108.39% | 15.49% | -16.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 85.83% | 81.88% | 108.39% | 15.49% | -16.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.83% | 81.88% | 108.39% | 15.49% | -16.45% |
| EBIT | 84.17% | 83.08% | -8.10% | -11.42% | -12.88% |
| EBITDA | 84.81% | 83.72% | -8.32% | -10.82% | -12.90% |
| EPS Basic | 99.88% | 99.81% | 103.11% | 44.47% | 45.82% |
| Normalized Basic EPS | 99.88% | 99.81% | 63.97% | 15.37% | 46.73% |
| EPS Diluted | 99.88% | 99.81% | 103.11% | 44.47% | 45.82% |
| Normalized Diluted EPS | 99.88% | 99.81% | 63.97% | 15.37% | 46.73% |
| Average Basic Shares Outstanding | 11,632.54% | 9,256.66% | 170.18% | 52.05% | 115.02% |
| Average Diluted Shares Outstanding | 11,632.54% | 9,256.66% | 170.18% | 52.05% | 115.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |